Tectonic Therapeutic, Inc.
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RX… Read more
Tectonic Therapeutic, Inc. (TECX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.058x
Based on the latest financial reports, Tectonic Therapeutic, Inc. (TECX) has a cash flow conversion efficiency ratio of -0.058x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-14.46 Million) by net assets ($251.33 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Tectonic Therapeutic, Inc. - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Tectonic Therapeutic, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Tectonic Therapeutic, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tectonic Therapeutic, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Perion Network
NASDAQ:PERI
|
0.009x |
|
TEMPLE + WEBSTER GRP
F:2Q9
|
N/A |
|
Shandong Binzhou Bohai Piston Co Ltd
SHG:600960
|
-0.043x |
|
Chun Yuan Steel Industry Co Ltd
TW:2010
|
0.019x |
|
Innovative Solutions and Support
NASDAQ:ISSC
|
0.046x |
|
BECLE S.A.B. DE C.V. 001
F:6BE
|
N/A |
|
China Union Holdings Ltd
SHE:000036
|
-0.005x |
|
Binh Duong Water Environment JSC
VN:BWE
|
0.013x |
Annual Cash Flow Conversion Efficiency for Tectonic Therapeutic, Inc. (2016–2025)
The table below shows the annual cash flow conversion efficiency of Tectonic Therapeutic, Inc. from 2016 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $251.33 Million | $-60.08 Million | -0.239x | +43.04% |
| 2024-12-31 | $140.78 Million | $-59.08 Million | -0.420x | -187.31% |
| 2023-12-31 | $-84.64 Million | $-40.68 Million | 0.481x | -77.43% |
| 2022-12-31 | $-45.65 Million | $-97.21 Million | 2.129x | +155.77% |
| 2021-12-31 | $-14.96 Million | $-12.45 Million | 0.832x | +314.30% |
| 2020-12-31 | $254.34 Million | $-98.80 Million | -0.388x | -6.78% |
| 2019-12-31 | $186.01 Million | $-67.67 Million | -0.364x | -18.06% |
| 2018-12-31 | $122.18 Million | $-37.65 Million | -0.308x | +93.67% |
| 2017-12-31 | $3.37 Million | $-16.38 Million | -4.868x | -549.46% |
| 2016-12-31 | $4.42 Million | $-3.31 Million | -0.750x | -- |